TNFRSF4 Protein (AA 31-130) (GST tag)
-
- Target Alle TNFRSF4 Proteine anzeigen
- TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
- Protein-Typ
- Recombinant
- Proteineigenschaft
- AA 31-130
-
Spezies
- Human
-
Quelle
- Wheat germ
- Aufreinigungstag / Konjugat
- Dieses TNFRSF4 Protein ist gelabelt mit GST tag.
- Applikation
- Western Blotting (WB), ELISA, Affinity Purification (AP), Antibody Array (AA)
- Verwendungszweck
- TNFRSF4 (Human) Recombinant Protein (Q01)
- Sequenz
- CVGDTYPSND RCCHECRPGN GMVSRCSRSQ NTVCRPCGPG FYNDVVSSKP CKPCTWCNLR SGSERKQLCT ATQDTVCRCR AGTQPLDSYK PGVDCAPCPP
- Produktmerkmale
- Human TNFRSF4 partial ORF ( NP_003318, 31 a.a. - 130 a.a.) recombinant protein with GST-tag at N-terminal.
- Aufreinigung
- in vitro wheat germ expression system
- Top Product
- Discover our top product TNFRSF4 Protein
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Kommentare
-
Preparation method: in vitro, wheat germ expression system
Product Quality tested by: 12.5% SDS-PAGE Stained with Coomassie Blue. - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- 50 mM Tris-HCI, 10 mM reduced Glutathione, pH =8.0 in the elution buffer.
- Handhabung
- Aliquot to avoid repeated freezing and thawing.
- Lagerung
- -80 °C
- Informationen zur Lagerung
- Best use within three months from the date of receipt of this protein.
-
- Target
- TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
- Andere Bezeichnung
- TNFRSF4 (TNFRSF4 Produkte)
- Synonyme
- TNFRSF4 Protein, ACT35 Protein, CD134 Protein, Ly-70 Protein, Ox40 Protein, TXGP1L Protein, Txgp1 Protein, OX40 Protein, TNF receptor superfamily member 4 Protein, tumor necrosis factor receptor superfamily, member 4 Protein, TNFRSF4 Protein, Tnfrsf4 Protein
- Hintergrund
-
Full Gene Name: tumor necrosis factor receptor superfamily, member 4
Synonyms: ACT35,CD134,OX40,TXGP1L - Gen-ID
- 7293
- NCBI Accession
- NM_003327
- Pathways
- Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
-